CN219517546U

CN219517546U - Transdermal drug delivery device

Info

Publication number: CN219517546U
Application number: CN202221973800.8U
Authority: CN
Inventors: 祁珍珍; 卢神州; 陶晓晟
Original assignee: Suzhou University
Current assignee: Suzhou University
Priority date: 2022-07-28
Filing date: 2022-07-28
Publication date: 2023-08-15
Anticipated expiration: 2032-07-28

Abstract

The utility model discloses a transdermal drug delivery device, which comprises a power supply, a switch, a fixed resistor, an adjustable resistor and a microneedle patch containing a drug, wherein the power supply, the switch and the adjustable resistor form a main loop; the fixed resistor is connected in parallel with the microneedle patch and then connected in series on the main loop, and the microneedle patch is a conductive microneedle patch; the microneedle patch is for releasing a drug outwardly upon energization. The voltage loaded on the microneedle patch can be adjusted by setting the adjustable resistor, and meanwhile, the fixed resistor is set to ensure safe use. The microneedle patch is a drug carrier and can realize conductivity. The transdermal drug delivery device has the advantages of fewer used components, small occupied space combined on the terminal, realization of miniaturization and portability, and adjustable voltage loaded on the microneedle patch.

Description

Transdermal drug delivery device

Technical Field

The utility model relates to the technical field of medical treatment and medical beauty, in particular to a transdermal drug delivery device.

Background

Transdermal administration refers to a method of administration where the drug is coated or applied to the surface of the skin. Can be administered as a systemic administration in addition to topical administration to the affected area of the skin. The medicine can directly penetrate into the skin from the cornea layer of the skin and the auxiliary structures of the skin such as hair follicle, sweat gland duct opening and the like, enter into capillary vessels and are distributed throughout the body through the body circulation. The administration route has the advantages of convenience, simplicity, lasting drug effect and the like, and is safe and free of liver first pass effect. However, general drugs are difficult to penetrate the skin due to the barrier effect of the stratum corneum, and the delivery rate is extremely slow. In order to improve the skin penetration effect of drugs, various techniques for promoting transdermal drug delivery have been developed. Among the techniques for opening skin passages by electric current are electroporation, ion electrodialysis, etc.

In electroporation, a high voltage pulse (typically > 100V) with a pulse width of microsecond to millisecond is applied to the skin surface to permeate it, a process which has been demonstrated to reversibly disrupt cell membrane and lipid bilayer structures in the skin. This combination can increase transdermal transport of DNA, vaccines, peptides and small molecule drugs by several orders of magnitude. The electrical resistance of the skin (stratum corneum) is several orders of magnitude higher than that of deep tissues. Thus, during the excitation process, a large potential drop occurs in the stratum corneum until electroporation occurs. Immediately following this, the electrical resistance drops rapidly to a great extent, which increases the potential drop of deeper tissues (e.g., epidermis, dermis, subcutaneous tissue). Such extremely high potential gradients often stimulate muscle tissue, nerves and sweat glands, creating a safety hazard that requires a voltage reduction to a safe voltage.

The electrodes on the skin surface in iontophoresis can trigger drug delivery through the stratum corneum under low voltage (< 10V) constant current (constant current) conditions. Unlike electroporation, iontophoresis hardly changes the permeability of the skin, and thus the main driving force is electrophoresis/electromigration of surface-charged small molecule drugs, followed by electroosmosis. Iontophoresis is generally only applicable to charged small molecules, however, and delivery depths are shallow, requiring transdermal delivery protocols for macromolecular drugs.

Chinese patent application CN202210263237.3 discloses a silk fibroin insulin microneedle patch which can be used for carrying medicine through a microneedle, puncturing epidermis and entering dermis and for transdermally releasing macromolecular medicine into dermis. But lack a solution to control the transdermal rate of the drug. Accordingly, it is necessary to provide a means of controlling the voltage to control the rate of drug delivery in the microneedles. The treatment equipment directly adopting the external power supply has complex structure, cannot realize portability and miniaturization, is difficult to control the loaded voltage and has high manufacturing cost.

Disclosure of Invention

In view of the above, in order to overcome the defects of the prior art, the utility model aims to provide a transdermal drug delivery device, which can reduce components and parts while ensuring perfect functions, and can control the voltage loaded on a microneedle patch so as to achieve the purpose of controlling intelligent transdermal drug delivery of macromolecular drugs.

In order to achieve the above purpose, the present utility model adopts the following technical scheme:

a transdermal drug delivery device comprises a power supply, a switch, a fixed resistor, an adjustable resistor and a microneedle patch containing a drug, wherein the power supply, the switch and the adjustable resistor form a main loop; the fixed resistor is connected in parallel with the microneedle patch and then connected in series on the main loop, and the microneedle patch is a conductive microneedle patch; the microneedle patch is for releasing a drug outwardly upon energization. The voltage loaded on the microneedle patch can be adjusted by setting the adjustable resistor, and meanwhile, the fixed resistor is set to ensure safe use. The microneedle patch is a drug carrier and can realize conductivity.

According to some preferred embodiments of the utility model, the power source is a dc power source.

According to some preferred embodiments of the utility model, the voltage of the power supply is 3V to 3.6V.

According to some preferred embodiments of the utility model, the power source is a rechargeable button lithium ion battery of 3V to 3.6V, or a non-rechargeable 3V button lithium manganese battery.

According to some preferred embodiments of the utility model, the fixed resistor has a resistance of 200 to 600Ω, preferably 500Ω.

According to some preferred embodiments of the utility model, the adjustable resistor has a resistance adjustment range of 200-2000 Ω.

According to some preferred embodiments of the utility model, the fixed resistor and the adjustable resistor are used to maintain a voltage applied to the microneedle patch within a safe voltage.

According to some preferred embodiments of the utility model, the safety voltage is between 0.6 and 1V. The safety voltage needs to ensure the use safety on one hand and needs to be matched with the micro-needle patch to realize response on the other hand.

According to some preferred embodiments of the utility model, an alarm assembly is arranged on the main circuit, and the alarm assembly is an indicator lamp and/or a buzzer.

According to some preferred embodiments of the utility model, the microneedle patch is a silk fibroin insulin microneedle patch disclosed in chinese patent application CN 202210263237.3.

Compared with the prior art, the utility model has the following advantages: the transdermal drug delivery device has the advantages of fewer used components and less occupied space when combined on a terminal, can realize miniaturization and portability of corresponding products, can simultaneously enable the voltage loaded on the microneedle patch to be adjustable, and can realize controllable release of drugs when combined with the microneedle patch.

Drawings

In order to more clearly illustrate the technical solutions of the embodiments of the present utility model, the drawings required for the description of the embodiments will be briefly described below, and it is apparent that the drawings in the following description are only some embodiments of the present utility model, and other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.

FIG. 1 is a schematic view showing the structure of a transdermal drug delivery device according to an embodiment of the present utility model;

in the drawing, R1 is a fixed resistor, and R2 is an adjustable resistor.

Detailed Description

In order to make the technical solution of the present utility model better understood by those skilled in the art, the technical solution of the present utility model will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present utility model, and it is apparent that the described embodiments are only some embodiments of the present utility model, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the present utility model without making any inventive effort, shall fall within the scope of the present utility model.

As shown in fig. 1, the drug delivery device in this embodiment includes a power source, a switch, an alarm assembly, a fixed resistor R1, an adjustable resistor R2, a microneedle patch containing a drug, and wires connected between the various components. The power supply, the switch, the alarm assembly and the adjustable resistor R2 form a main loop, and the fixed resistor R1 is connected with the microneedle patch in parallel and then connected to the main loop. Namely, the fixed resistor R1 is connected in parallel with the microneedle patch and then connected in series with a power supply, the adjustable resistor R2 and a switch. The alarm assembly in this embodiment is an indicator light.

The power supply is a direct current power supply, the voltage range is 3-3.6V, and various small-sized energy output products can be selected, such as: 3.6V rechargeable lithium ion coin cells (LIR series), 3V rechargeable lithium ion coin cells (ML or VL series), non-rechargeable including 3V lithium manganese coin cells (CR series), etc.

The resistance of the fixed resistor R1 is 500 omega; the resistance of the adjustable resistor R2 is adjusted to be 200-2000 omega. The fixed resistor R1 and the adjustable resistor R2 are matched to maintain the voltage loaded on the microneedle patch within 0.6-1V of the safe voltage. The safety voltage needs to ensure the use safety on one hand and needs to be matched with the micro-needle patch to realize response on the other hand.

The microneedle patch adopted in the embodiment contains a drug, is a drug carrier, can realize conductivity at the same time, and is used for releasing the drug outwards when being electrified, and is preferably an electrically-responsive microneedle patch so as to realize adjustment of matching voltage and realize controllable release of the drug. Through adjusting adjustable resistance R2's resistance value, can adjust the voltage of loading on the microneedle paster, realize the controllable release of medicine, set up fixed resistance R1 simultaneously and guarantee safe in utilization. Specifically, the microneedle patch may be in the form of a conductive polymer microneedle patch containing a drug, a microneedle patch of a polymer hydrogel responsive to electrical stimulation, or a drug-loaded microneedle patch as disclosed in patent application No. cn202010524703.X, preferably a silk fibroin insulin microneedle patch as disclosed in chinese patent application No. CN 202210263237.3.

The above embodiments are only for illustrating the technical concept and features of the present utility model, and are intended to enable those skilled in the art to understand the present utility model and to implement the same, but are not intended to limit the scope of the present utility model, and all equivalent changes or modifications made according to the spirit of the present utility model should be included in the scope of the present utility model.

Claims

1. A transdermal drug delivery device, comprising a power supply, a switch, a fixed resistor, an adjustable resistor and a microneedle patch containing a drug, wherein the power supply, the switch and the adjustable resistor form a main loop; the fixed resistor is connected in series with the microneedle patch on the main loop after being connected in parallel, and the microneedle patch is used for releasing the medicine outwards when being electrified.

2. A transdermal drug delivery device according to claim 1, wherein: the power supply is a direct current power supply.

3. A transdermal drug delivery device according to claim 2, wherein: the voltage of the power supply is 3V-3.6V.

4. A transdermal drug delivery device according to claim 3, wherein: the power supply is a rechargeable button lithium battery or a non-rechargeable button lithium-manganese battery.

5. A transdermal drug delivery device according to claim 1, wherein: the resistance of the fixed resistor is 200-600Ω.

6. A transdermal drug delivery device according to claim 1, wherein: the resistance adjustment range of the adjustable resistor is 200-2000 omega.

7. A transdermal drug delivery device according to claim 1, wherein: the fixed resistor and the adjustable resistor are used for maintaining the voltage loaded on the microneedle patch within a safe voltage.

8. A transdermal drug delivery device according to claim 7, wherein: the safety voltage is 0.6-1V.

9. A transdermal drug delivery device according to claim 1, wherein: the main loop is provided with an alarm component which is an indicator lamp and/or a buzzer.